Success Metrics

Clinical Success Rate
96.0%

Based on 24 completed trials

Completion Rate
96%(24/25)
Active Trials
0(0%)
Results Posted
38%(9 trials)
Terminated
1(3%)

Phase Distribution

Ph phase_2
6
20%
Ph phase_1
5
17%
Ph phase_4
6
20%
Ph phase_3
10
33%

Phase Distribution

5

Early Stage

6

Mid Stage

16

Late Stage

Phase Distribution27 total trials
Phase 1Safety & dosage
5(18.5%)
Phase 2Efficacy & side effects
6(22.2%)
Phase 3Large-scale testing
10(37.0%)
Phase 4Post-market surveillance
6(22.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

92.3%

24 of 26 finished

Non-Completion Rate

7.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

30

all time

Status Distribution
Active(1)
Completed(24)
Terminated(2)
Other(3)

Detailed Status

Completed24
unknown3
Terminated1
Withdrawn1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
30
Active
0
Success Rate
96.0%
Most Advanced
Phase 4

Trials by Phase

Phase 15 (18.5%)
Phase 26 (22.2%)
Phase 310 (37.0%)
Phase 46 (22.2%)

Trials by Status

terminated13%
unknown310%
completed2480%
withdrawn13%
enrolling_by_invitation13%

Recent Activity

Clinical Trials (30)

Showing 20 of 30 trialsScroll for more
NCT05826912Phase 2

Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury

Enrolling By Invitation
NCT05122182Phase 2

Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19

Terminated
NCT03847506Phase 4

Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets

Completed
NCT02211638

Candesartan Cilexetil Special Drug Use Surveillance 「Challenge - Quality Control」

Completed
NCT02332824Phase 2

A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria

Completed
NCT01734096Phase 4

Renal Response to Lower Body Negative Pressure in Pre-hypertensive States

Completed
NCT02047019Phase 3

Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil

Withdrawn
NCT01611077Phase 4

Efficacy and Safety of a Therapy Change From Candesartan 32 mg to Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg

Completed
NCT02166697

Blopress Tablets Specified Drug-use Survey "Hypertension: Survey on Patients With Metabolic Syndrome"

Completed
NCT02709187Phase 1

DP-R208 Pharmacokinetic Study

Completed
NCT01613209Phase 3

Sevicontrol-1: Efficacy and Safety of a Fixed Combination of Olmesartan/ Amlodipine

Completed
NCT02707224Phase 1

Clinical Trial to Compare the Pharmacokinetics of DP-R208

Completed
NCT02609711Phase 1

Investigate a Interaction of Candesartan and Atorvastatin in Healthy Male Sugjects

Unknown
NCT00252733Phase 3

Diabetic Retinopathy Candesartan Trials

Completed
NCT00184587Phase 2

Prophylactic Treatment of Episodic Cluster Headache

Completed
NCT01052272Phase 2

Impact of Diabetes on Left Ventricular Remodeling

Completed
NCT01135212Phase 3

The Clinical Study to Evaluate the Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension

Completed
NCT00573430Phase 4

ARIA (Atacand Renoprotection In NephropAthy Pt.)

Completed
NCT00690612Phase 3

Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics)

Completed
NCT00120003Phase 3

Scandinavian Candesartan Acute Stroke Trial (SCAST)

Completed

Drug Details

Intervention Type
DRUG
Total Trials
30